Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin‐Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti‐PCSK9 Antibody in Statin‐Intolerant Subjects 3 (GAUSS‐3) Trial

Statins are the accepted standard for lowering low‐density lipoprotein cholesterol (LDL‐C). However, 5% to 10% of statin‐treated patients report intolerance, mostly due to muscle‐related adverse effects. Challenges exist to objective identification of statin‐intolerant patients. Evolocumab is a mono...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Cardiol
Huvudupphovsmän: Nissen, Steven E., Dent‐Acosta, Ricardo E., Rosenson, Robert S., Stroes, Erik, Sattar, Naveed, Preiss, David, Mancini, G.B. John, Ballantyne, Christie M., Catapano, Alberico, Gouni‐Berthold, Ioanna, Stein, Evan A., Xue, Allen, Wasserman, Scott M., Scott, Rob, Thompson, Paul D.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Wiley Periodicals, Inc. 2016
Ämnen:
Trial Designs
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6490723/
https://ncbi.nlm.nih.gov/pubmed/26946077
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.22518
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk